Galectin Therapeutics reported $1.52M in Selling and Administration Expenses for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Abbvie ABBV:US USD 3.21B 4M
Bristol Myers Squibb BMY:US USD 2.27B 336M
Galectin Therapeutics GALT:US USD 1.52M 64K
Gilead Sciences GILD:US USD 2.02B 807M
Idera Pharmaceuticals IDRA:US USD 2.27M 391K
Intercept Pharmaceuticals ICPT:US USD 55.29M 12.02M
Merk MRK:US USD 2.63B 134M
Regulus Therapeutics RGLS:US USD 4.44M 2.18M
Vital Therapies VTL:US USD 3.62M 43K
YTE INCY:US USD 272.82M 6.36M